Mid-Atlantic BioTherapeutics: Funding, Investors & Team (Sep 2026)
Mid-Atlantic BioTherapeutics is concentrating on the advancement and marketing of a new immunotherapy for infectious diseases, aiming to combat antibiotic resistance and develop innovative treatments for viral diseases, emerging infections, and biodefense.
Mid-Atlantic BioTherapeutics has raised $5.0M across 1 funding round on record, the most recent an undisclosed round of $5.0M announced in Jun 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mid-Atlantic BioTherapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Mid-Atlantic BioTherapeutics Funding Rounds
Mid-Atlantic BioTherapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Mid-Atlantic BioTherapeutics Funding Compared to Other Biotechnology Startups
Mid-Atlantic BioTherapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mid-Atlantic BioTherapeutics in Biotechnology and Doylestown
Companies Similar to Mid-Atlantic BioTherapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Mid-Atlantic BioTherapeutics Funding FAQs
What does Mid-Atlantic BioTherapeutics do?
Mid-Atlantic BioTherapeutics is concentrating on the advancement and marketing of a new immunotherapy for infectious diseases, aiming to combat antibiotic resistance and develop innovative treatments for viral diseases, emerging infections, and biodefense.
How much funding has Mid-Atlantic BioTherapeutics raised?
Mid-Atlantic BioTherapeutics has raised $5.0M across 1 round on record. The most recent is an undisclosed round of $5.0M announced in Jun 2024.
When did Mid-Atlantic BioTherapeutics last raise funding?
Mid-Atlantic BioTherapeutics' most recent funding round on record is an undisclosed round of $5.0M, announced in Jun 2024.
Who founded Mid-Atlantic BioTherapeutics?
FundedIQ lists David Jobes (Founder) at Mid-Atlantic BioTherapeutics.
Where is Mid-Atlantic BioTherapeutics headquartered?
Mid-Atlantic BioTherapeutics is based in Doylestown, Pennsylvania, United States.
How many employees does Mid-Atlantic BioTherapeutics have?
Mid-Atlantic BioTherapeutics is in the 1-10 employee band.
How does Mid-Atlantic BioTherapeutics' funding compare to other Biotechnology startups?
Mid-Atlantic BioTherapeutics' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Mid-Atlantic BioTherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mid-Atlantic BioTherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.